- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively

Read the rest here:
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Expect to disclose initial SC262 clinical data in 2024 Expect to disclose initial SC262 clinical data in 2024

Excerpt from:
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T...

– KRIYA-586 is designed to be a one-time treatment delivered by focal peribulbar injection, that encodes an antibody blocking the Insulin-Like Growth Factor 1 Receptor (IGF-1R), a clinically validated drug target in Thyroid Eye Disease (TED) –

See the rest here:
Kriya Announces Gene Therapy Program for Thyroid Eye Disease

AUSTIN, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced the completion of a previously announced distribution of warrants (the “Warrants”) to its shareholders. The Warrants now trade on Nasdaq under the ticker SAVAW.

Read this article:
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

Basel, January 5, 2024— Novartis announced today that it has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan / USAN: lutetium Lu 177 vipivotide tetraxetan) at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States. The 70,000-square foot site, the company’s second US location, is designed specifically for RLT manufacturing and is now the largest and most advanced Novartis facility of its kind in the world. The Indianapolis site represents the next phase of RLT manufacturing growth as this new addition brings substantial supply increases for the foreseeable future.

Originally posted here:
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024. The presentation will be primarily focused on the recent commencement of the phase 2 trial with intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s. Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.

Link:
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce that it will be presenting at Biotech Showcase in San Francisco, January 8-10 2024. The OKYO management team will also be participating in one-on-one partnering meetings throughout the conference.

Read more:
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Monthly information relative to the total number of voting rights and shares composing the share capital

Go here to read the rest:
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT.

Read the original:
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)

—ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)—

Follow this link:
BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to...